Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease

Metabolism: Clinical and Experimental

Volumn 52, Issue 10, 2003, Pages 1279-1286

  Dane Stewart, Cheryl A ^a,b,c   Watts, Gerald F ^a,b,c   Pal, Sebely ^a,b,c   Chan, Dick ^a,b,c   Thompson, Peter ^a,b,c   Hung, Joseph ^a,b,c   Mamo, John C L ^a,b,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c Sir Charles Gairdinar Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; ATORVASTATIN; CHOLESTEROL; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LATHOSTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MARKER; PLACEBO; TRIACYLGLYCEROL; APOLIPOPROTEIN B; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ANGIOCARDIOGRAPHY; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIET RESTRICTION; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; FEMALE; HOMEOSTASIS; HUMAN; HUMAN CELL; LIVER FUNCTION; MALE; MONONUCLEAR CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; TRIACYLGLYCEROL BLOOD LEVEL; ADULT; AGED; BLOOD; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-48; APOLIPOPROTEINS B; AREA UNDER CURVE; CHYLOMICRONS; CORONARY DISEASE; FASTING; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PYRROLES; RECEPTORS, LDL; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0242335745     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(03)00281-6     Document Type: Article

References (44)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994
2. Sacks FM, Pfeffer MA, Moyle LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996
3. Karpe F, Steiner G, Uffelman K, et al: Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 106:83-97, 1994
4. Proctor SD, Mamo JCL: Arterial fatty lesions have increased uptake of chylomicron remnants but not low-density lipoproteins. Coron Artery Dis 7:239-245, 1996
5. Mamo JCL: Atherosclerosis as a post-prandial disease. Endocrinol Metab 2:229-44, 1995
6. Kugiyama K, Doi H, Takazoe K, et al: Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 99:2858-2860, 1999
7. Lundman P, Eriksson M, Schenck-Gustafsson K, et al.: Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation 96:3266-3268, 1997
8. Vogel RA, Corretti MC, Plotnick GD: Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 79:1682-1686, 1997
9. Celermajer DS, Sorensen KE, Gooch VM, et al: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111-1115, 1992
10. Simons LA, Dwyer T, Simons J, et al.: Chylomicrons and chylomicron remnants in coronary artery disease: A case control study. Atherosclerosis 65:181-189, 1987
11. Groot PH, Van Stiphout WAHJ, Krauss XH, et al: Postprandial lipoprotein metabolism in normolipidaemic men with and without coronary disease. Arterioscler Thromb Vasc Biol 11:653-662, 1991
12. Weintraub MS, Grosskopf I, Rassin T, et al.: Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: Case control study over three years. BMJ 312:935-939, 1996
13. 48 and triglyceride responses in normolipidaemic women with greater than 70% stenotic coronary artery disease: A case-control study. Atherosclerosis 124:221-235, 1996
14. Braun D, Gramlich A, Brehme U, et al: Postprandial lipaemia after a moderate fat challenge in normolipidaemic men with and without coronary artery disease. J Cardiol Risk 4:143-149, 1997
15. Przybycień K, Kornacewicz-Jach Z, Torbus-Lisiecka B, et al.: Is abnormal postprandial lipaemia a familial risk factor for coronary artery disease in individuals with normal fasting concentrations of triglycerides and cholesterol? Coron Artery Dis 11:377-381, 2000
16. Kugiyama K, Doi H, Motoyama T, et al: Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 97:2519-2526, 1998
17. Doi H, Kugiyama K, Oka K, et al: Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 102:670-676, 2000
18. Cohn JS: Postprandial lipemia: Emerging evidence for atherogenicity of remnant lipoproteins. Can J Cardiol 14:18B-27B, 1998
19. Watts GF, Cummings MH, Umplebly M, et al: Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: Pathophysiological and therapeutic implications. Eur J Clin Invest 25:559-567, 1995
20. Aguilar-Salinas CA, Barrett H, Schonfeld G: Metabolic modes of action of the statins in hyperlipoproteinemias. Atherosclerosis 141:203-207, 1998
21. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolaemia. Am J Cardiol 80:39-44, 1997
22. Ginsberg HN: Hypertriglyceridemia: New insights and new approaches to pharmacologic therapy. Am J Cardiol 87:1174-1180, 2001
23. Burnett JR, Barrett PHR, Vicini P: The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance of postprandial triglyceride-rich lipoproteins in miniature pigs. Arterioscler Thromb Vasc Biol 18:1906-1914, 1998
24. Parhofer KG, Barrett PHR, Schwandt P: Atorvastatin improves postprandial lipoprotein metabolism in normolipdaemic subjects. J Clin Endocrinol Metab 85:4224-4230, 2000
25. Kempen HJM, Glatz JFC, Gevers Leuven JA, et al: Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res 29:1149-1155, 1988
26. 48 using an antibody to human apolipoprotein B and enhanced chemiluminescence. Ann Clin Biochem 34:185-189, 1997
27. Mamo JCL, Watts GF, Barrett PH: Postprandial dyslipidemia in men with visceral obesity: An effect of reduced LDL receptor expression? Am J Physiol 281:E626-E632, 2001
28. Nakajima K, Saito T, Tamura A, et al.: Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 223:53-71, 1993
29. Roach RP, Hosking J, Clifton PM, et al.: The effects of hypercholesterolaemia, simvastatin and dietary fat on the low density lipoprotein receptor of unstimulated mononuclear cells. Atherosclerosis 103:245-254, 1993
30. Mori TA, Croft KD, Puddey IB, et al: Analysis of native and oxidised low-density lipoprotein oxysterols using gas chromatography-mass spectrometry with selective ion monitoring. Redox Rep 2:25-34, 1996
31. Jones P, Kafonek S, Laurora I, et al.: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolaemia (the CURVES study). Am J Cardiol 81:582-587, 1998
32. Halkes CJM, Van Dijk H, De Jaegere PPT, et al: Postprandial increase of complement component 3 in normolipidaemic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21:1526-1530, 2001
33. Smith D, Watts GF, Dane-Stewart C, et al: Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. Eur J Clin Invest 29:204-209, 1999
34. Santos RD, Sposito AC, Ventura LI, et al: Effect of pravastatin on plasma removal of a chylomicron like emulsion in men with coronary artery disease. Am J Cardiol 15:1163-1166, 2000
35. Twickler TB, Dallinga-Thie GM, De Valk HW, et al: High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 20:2422-2427, 2000
36. Innerarity TL, Mahley RW: Enhanced binding by cultured human fibroblasts of apoE continuing lipoproteins as compared with low density lipoproteins. Biochemistry 17:1440-1447, 1978
37. Grieve DJ, Avella MA, Elliott J, et al: The influence of chylomicron remnants on endothelial cell function in the isolated perfused rat aorta. Atherosclerosis 139:273-281, 1998
38. Wilmink HW, Twickler MB, Banga JD, et al: Effect of statin versus fibrate on postprandial endothelial dysfunction: Role of remnant-like particles. Cardiovasc Res 50:577-582, 2001
39. Suwaidi JA, Hamasaki S, Higano ST, et al: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101:948-954, 2000
40. Schächinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101:1899-1906, 2000
41. Sacks FM, Alaupovic P, Moye LA, et al: VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events trial. Circulation 102:1886-1892, 2000
42. Simes RJ, Marschner IC, Hunt D, et al: The LIPID Study Investigators. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial. To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 105:1162-1169, 2002
43. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1997
44. Collins R, Armitage J, Parish S, et al.: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360:7-22, 2002